Latest Nasdaq News

Centuria Capital Group is leveraging its $21.8 billion real estate platform to scale AI compute infrastructure through ResetData, aiming to capture growing sovereign and enterprise demand amid global supply constraints.

5E Advanced Materials has requested suspension of its shares from ASX trading to enable its removal from the official list, marking a significant shift in its market presence.

Anteris Technologies Global Corp. has initiated an at-the-market equity offering to raise up to US$250 million, aiming to accelerate development of its DurAVR transcatheter heart valve and support general corporate needs.

IperionX has commissioned a cutting-edge six-axis SACMI powder metallurgy press in Virginia, tripling its titanium manufacturing capacity and enabling production of complex components for defense and aerospace markets.

Nova Minerals CEO Christopher Gerteisen highlighted progress on the Estelle Project at the Alaska Sustainable Energy Conference, emphasizing the company’s role in establishing a US domestic antimony supply chain backed by US$43.4 million in government funding.

Alterity Therapeutics has showcased compelling Phase 2 data for ATH434 in Multiple System Atrophy, paving the way for a Phase 3 trial with FDA engagement targeted for mid-2026.

American Tungsten & Antimony Ltd (ASX: AT4) has raised A$10 million through a strongly supported placement and secured a 40% Utah state tax credit, underpinning its strategy to develop a domestic US supply chain for tungsten and antimony ahead of a planned Nasdaq listing.

Jindalee Lithium has launched a non-renounceable entitlement offer priced at A$0.46 per share, including attaching options exercisable at A$0.60, aiming to raise capital by early June 2026.

Red Mountain Mining has gained NSW Resources Regulator approval for a 32-hole reverse circulation drilling program at its Oaky Creek Antimony-Gold Project, targeting a significant 3km strike of orogenic mineralisation. An orientation Induced Polarisation survey has been completed to refine drill targeting, with results expected soon.

Elevra Lithium has raised A$275 million through a fully underwritten institutional placement to fund its North American Lithium expansion and Moblan project development, supported by strong institutional demand.

Anteris Technologies reported a $22.9 million net loss in Q1 2026 but bolstered its cash position to $283 million following a $320 million capital raise. The company is scaling manufacturing and clinical activities for its DurAVR transcatheter heart valve, with US patient enrolment now underway in the pivotal PARADIGM Trial.

5E Advanced Materials secures a decade-long boric acid offtake agreement and advances boron product development, while reporting a $12.1 million quarterly loss and planning ASX delisting.